| scholarly article | Q13442814 |
| P50 | author | Ignacio Torres Aleman | Q43179267 |
| Eva Carro | Q43272741 | ||
| P2093 | author name string | C Lopez-Lopez | |
| C Carrascosa | |||
| L Espejo | |||
| S Torrado | |||
| J J Torrado | |||
| P2860 | cites work | The effect of the frequency of subcutaneous insulin-like growth factor-1 administration on weight gain in growth hormone deficient mice | Q28588682 |
| Investigation of protein/carbohydrate interactions in the dried state. 2. Diffuse reflectance FTIR studies. | Q30329848 | ||
| Circulating insulin-like growth factor I mediates the protective effects of physical exercise against brain insults of different etiology and anatomy. | Q34084703 | ||
| Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches | Q34156542 | ||
| Serum growth factors and neuroprotective surveillance: focus on IGF-1. | Q34265977 | ||
| Drug and gene delivery to the brain: the vascular route | Q35003855 | ||
| Pharmacological characteristics of parenteral IGF-I administration | Q35101010 | ||
| Macromolecular permeability across the blood-nerve and blood-brain barriers | Q35526610 | ||
| Insulin-like growth factor I restores motor coordination in a rat model of cerebellar ataxia | Q35802448 | ||
| Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations | Q38667678 | ||
| Continuous versus intermittent subcutaneous infusion of octreotide in the treatment of acromegaly | Q40526147 | ||
| Neurotrophic factor therapy for nervous system degenerative diseases | Q40590924 | ||
| Plasma insulin-like growth factor I and IGF binding protein 3 levels in patients with acute cerebral ischemic injury | Q40882396 | ||
| Kinetic analysis of the disposition of insulin-like growth factor 1 in healthy volunteers | Q43756968 | ||
| Effects of insulin-like growth factor on weight gain in chronic hypoxic rats | Q47187435 | ||
| IGF in the clinic | Q47857147 | ||
| Low levels of insulin-like growth factor-I in cerebrospinal fluid in children with autism | Q48779818 | ||
| Circulating insulin-like growth factor I mediates effects of exercise on the brain. | Q49084468 | ||
| The insulin-like growth factor I system in cerebellar degeneration. | Q49107088 | ||
| Neurodegeneration is associated to changes in serum insulin-like growth factors | Q49157579 | ||
| Insulin-like growth factors and insulin-like growth factor binding proteins in cerebrospinal fluid and serum of patients with dementia of the Alzheimer type | Q53201609 | ||
| Aging as a major risk for degenerative diseases of the central nervous system. | Q53314938 | ||
| Sustained release of recombinant human insulin-like growth factor-I for treatment of diabetes. | Q54050413 | ||
| Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency | Q72554457 | ||
| Alteration of IGF system gene expression during the postnatal development of pcd mice | Q73170307 | ||
| Solvent effects on the solubility and physical stability of human insulin-like growth factor I | Q73371162 | ||
| Controlled release of recombinant insulin-like growth factor from a novel formulation of polylactide-co-glycolide microparticles | Q73413346 | ||
| Stabilizing insulin-like growth factor-I in poly(D,L-lactide-co-glycolide) microspheres | Q73413373 | ||
| Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group | Q73966063 | ||
| P433 | issue | 4 | |
| P921 | main subject | neurodegeneration | Q1755122 |
| microsphere | Q1759020 | ||
| preproinsulin | Q7240673 | ||
| P304 | page(s) | 707-714 | |
| P577 | publication date | 2004-02-01 | |
| P1433 | published in | Biomaterials | Q15751139 |
| P1476 | title | Microspheres containing insulin-like growth factor I for treatment of chronic neurodegeneration | |
| P478 | volume | 25 |
| Q34079647 | Agile delivery of protein therapeutics to CNS |
| Q84383056 | Animal models of human cerebellar ataxias: a cornerstone for the therapies of the twenty-first century |
| Q81235261 | Central actions of liver-derived insulin-like growth factor I underlying its pro-cognitive effects |
| Q35432628 | Controlled release of IGF-1 and HGF from a biodegradable polyurethane scaffold |
| Q45981067 | Delayed IGF-1 treatment reduced long-term hypoxia-ischemia-induced brain damage and improved behavior recovery of immature rats. |
| Q48298661 | Disturbed cross talk between insulin-like growth factor I and AMP-activated protein kinase as a possible cause of vascular dysfunction in the amyloid precursor protein/presenilin 2 mouse model of Alzheimer's disease |
| Q63972416 | Electrospraying, a Reproducible Method for Production of Polymeric Microspheres for Biomedical Applications |
| Q41856841 | IGF-1 in Friedreich's Ataxia - proof-of-concept trial |
| Q36003262 | IGF-1 in autosomal dominant cerebellar ataxia - open-label trial |
| Q36449180 | Insulin-like growth factor I is required for vessel remodeling in the adult brain |
| Q35189943 | Insulin-like growth factor-I mitigates motor coordination deficits associated with neonatal alcohol exposure in rats |
| Q28742839 | Neurotrophic effects of a cyanine dye via the PI3K-Akt pathway: attenuation of motor discoordination and neurodegeneration in an ataxic animal model |
| Q48832254 | Regulation of the phosphatase calcineurin by insulin-like growth factor I unveils a key role of astrocytes in Alzheimer's pathology. |
| Q40329109 | Spinocerebellar ataxia type 7 cerebellar disease requires the coordinated action of mutant ataxin-7 in neurons and glia, and displays non-cell-autonomous bergmann glia degeneration. |
| Q39971441 | Sustained release of TGFbeta3 from PLGA microspheres and its effect on early osteogenic differentiation of human mesenchymal stem cells |
| Q64104414 | The Role of Insulin-Like Growth Factors and Insulin-Like Growth Factor-Binding Proteins in the Nervous System |
| Q47745496 | The ataxic Syrian hamster: an animal model homologous to the pcd mutant mouse? |
| Q38050840 | Thymosin β4 sustained release from poly(lactide-co-glycolide) microspheres: synthesis and implications for treatment of myocardial ischemia |
Search more.